arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Indivior Pharmaceuticals, Inc.

INDV

$38.84 ▲ +0.18 (+0.47%) at close

5 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Moderately Bullish

auto_awesome

Analytical Summary

Indivior Pharmaceuticals, Inc. shows strong fundamentals with top-quartile Profit Margin (%) and Debt to Equity. However, watch Return on Common Equity (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $4.9B

Dividend Yield —

Revenue Growth 4.3% ↘

Op. Margin 21.1% ↗

ROIC 119.9% ↗

FCF / Share $-0.74 ↘

Trailing P/E 23.1x

Price / Book —

FCF Yield —

Debt / Equity -2.96

info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.24B

↑ +4.3% —

Net Income Profit after all expenses

$210.00M

↑ +2900.0% —

Operating Margin Operating profit as % of sales

21.1%

↑ +561.1% 77th

FCF / Share Free cash flow per share

$-0.74

↓ -1503.0% —

Long-Term Debt Long-term obligations

$290.00M

↓ -7.9% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)
Operating Margin (%)Operating Margin (%) is in the top quartile
Profit Margin (%)Profit Margin (%) is in the top quartile

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns

Financial Health ↓

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗
Revenue Growth YoY (%)	4.3% Caution ↓ Caution Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-46%)	8.7% Fair Fair Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+9%)	21.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+166%)	—	—
EPS Growth YoY (%)	3260.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	-193.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	2900.0% Excellent Excellent Year-over-year change in net income	N/M	-193.2% Weak Weak Year-over-year change in net income	N/M	—
FCF Growth YoY (%)	N/M	N/M	-3372.2% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	11.2% Good Good Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗
Operating Margin (%) (%)	21.1% Good ↑ Good Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+41%)	3.2% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-79%)	-14.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-195%)	-9.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-160%)	—
Effective Tax Rate (%) (%)	12.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	65.0% Weak ↑ Weak Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	13.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	49.4% Weak Weak Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	16.9% Good ↑ Good Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+41%)	0.6% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-95%)	-11.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-198%)	-4.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-141%)	—
FCF Margin (%) (%)	-7.5% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	0.6% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-28.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-1.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	-0.44x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.00x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	2.39x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	0.20x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗
Return on Invested Capital (%)	119.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-60.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-293.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	204.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	21.8% Excellent ↑ Excellent Improving Operating profit relative to total assets Optimal: > 10%	2.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-8.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-214.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1529%)	-2.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-114%)	67.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+350%)	220.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1367%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗
Debt to Equity (x)	-2.96x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-593%)	-0.93x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-256%)	-1.24x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-307%)	—	—
Interest Coverage (x)	6.89x Good ↑ Good Improving Operating income divided by interest expense Optimal: > 5x	1.27x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-5.78x Weak Weak Operating income divided by interest expense Optimal: > 5x	-4.26x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$95.00M	$-4.00M	$-79.00M	—	—
Debt / EBITDA (x)	1.07x Good ↓ Good Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	5.83x Weak Weak Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.68x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗
Revenue per Share (USD)	$9.91	$9.00	$7.98	$6.48	—
Basic EPS, GAAP (USD)	$1.68	$0.05	$-0.94	$-0.32	—
Free Cash Flow per Share (USD)	$-0.74	$0.05	$-2.25	$-0.06	—
Book Value per Share (USD)	$-0.78	$-2.55	$-1.39	$-0.14	—
Tangible Book Value per Share (USD)	$-0.80	$-2.57	$-1.43	$-0.14	—
Basic Weighted Avg Shares (shares)	125.00M	132.00M	137.00M	139.00M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗
Working Capital (USD)	$-262.00M	$-97.00M	$-24.00M	—	—
LT Debt (USD)	$290.00M	$315.00M	$237.00M	—	—
Total Equity (USD)	$-98.00M	$-337.00M	$-191.00M	$-20.00M	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗
Sales/Revenue/Turnover (USD)	$1.24B	$1.19B	$1.09B	$901.00M	—
Depreciation Expense (USD)	$10.00M	$16.00M	$15.00M	$16.00M	—
Net Income, GAAP (USD)	$210.00M	$7.00M	$-129.00M	$-44.00M	$205.00M
Operating Cash Flow (USD)	$-27.00M	$36.00M	$-300.00M	$-4.00M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters

Indivior Pharmaceuticals, Inc.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare INDV with peers